A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers

This is a randomized, double‐blind, single‐dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and tolerability of BS‐503a, a proposed bevacizumab biosimilar. A total of 114 male healthy subjects were randomized (1:1) to receive a single 3 mg/kg intravenous dose of eithe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tajima, Naoyuki, Martinez, Alberto, Kobayashi, Fumiaki, He, Ling, Dewland, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368956/
https://www.ncbi.nlm.nih.gov/pubmed/28357118
http://dx.doi.org/10.1002/prp2.286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368956/
https://www.ncbi.nlm.nih.gov/pubmed/28357118
http://dx.doi.org/10.1002/prp2.286

Ejemplares similares